menu
    • menu
    [{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"HGCO19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Gennova Biopharmaceuticals \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"Gennova Biopharmaceuticals \/ CEPI"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"HDT Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"HGCO19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Gennova Biopharmaceuticals \/ HDT Biotech Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Gennova Biopharmaceuticals \/ HDT Biotech Corporation"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gennova Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"HDT Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Gennova Biopharmaceuticals \/ Gennova Biopharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Gennova Biopharmaceuticals \/ Gennova Biopharmaceuticals"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"HDT Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ HDT Bio Corp","highestDevelopmentStatusID":"7","companyTruncated":"Gennova Biopharmaceuticals \/ HDT Bio Corp"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"mRNA-based Vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gennova Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"mRNA-based Vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"mRNA-based Vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gennova Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"mRNA-based Vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"mRNA-based Vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gennova Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"mRNA Covid-19 Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gennova Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Covid-19 Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gennova Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"mRNA Covid-19 Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gennova Biopharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Gennova Biopharmaceuticals

    Menu

    Gennova Biopharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA Covid-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Regulator Approves First Omicron-Specific MRNA Vaccine from India

                            Details : Gemcovac-19 is the first approved mRNA based Covid-19 vaccine developed with the use of genetically engineered mRNA which instructs the cells to make the S-protein found on the surface of the Covid-19 virus, causing the body to create antibodies.

                            Brand Name : Gemcovac-19

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            June 20, 2023

                            Lead Product(s) : mRNA Covid-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Covid-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Drug Panel May Review Gennova's mrna Omicron Booster Vaccine

                            Details : Gemcovac-19 is the first approved mRNA based Covid-19 vaccine developed with the use of genetically engineered mRNA which instructs the cells to make the S-protein found on the surface of the Covid-19 virus, causing the body to create antibodies.

                            Brand Name : Gemcovac-Om

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            April 18, 2023

                            Lead Product(s) : Covid-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA Covid-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gennova Biopharma Seeks DCGI Nod for Its Omicron Booster

                            Details : Gemcovac-19 is the first approved mRNA based Covid-19 vaccine developed with the use of genetically engineered mRNA which instructs the cells to make the S-protein found on the surface of the Covid-19 virus, causing the body to create antibodies.

                            Brand Name : Gemcovac-19

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            March 21, 2023

                            Lead Product(s) : mRNA Covid-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NTAGI Likely to Discuss Soon Data of India's First mRNA Vaccine Against COV

                            Details : Gemcovac-19, the first mRNA Covid-19 vaccine developed in India, and only third mRNA vaccine to be approved for COVID-19 in the world, received the Emergency Use Authorization (EUA) from DCGI.

                            Brand Name : GEMCOVAC-19

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            July 14, 2022

                            Lead Product(s) : mRNA-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            DCGI Approves Indigenous MRNA Covid Jab for Emergency Use in 18 Yrs & Above

                            Details : HGCO19 (mRNA-based Vaccine) has already demonstrated safety, immunogenicity, neutralization antibody activity in rodent models, neutralizing antibody response of vaccine in mice and non-human primates was comparable with sera from convalescent patients o...

                            Brand Name : HGCO19

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            June 29, 2022

                            Lead Product(s) : mRNA-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gennova Closes in On Nod for mRNA Vax Developed in India

                            Details : HGCO19 (mRNA-based Vaccine) has already demonstrated safety, immunogenicity, neutralization antibody activity in rodent and non-human primate models, neutralizing antibody response of vaccine in mice and non-human primates was comparable with sera from p...

                            Brand Name : HGCO19

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            June 10, 2022

                            Lead Product(s) : mRNA-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gennova Biopharma Submits Final Vaccine Trial Data to Regulator

                            Details : Company has conducted phase-2/3 trials of vaccine candidates to evaluate its safety, immunogenicity and tolerability on 4,000 participants, for first indigenously developed HGCO19, mRNA vaccine for Covid-19.

                            Brand Name : HGCO19

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            March 12, 2022

                            Lead Product(s) : mRNA-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            India's First Homegrown mRNA COVID-19 Vaccine Currently Under Final Clinical Trial Stages: Govt

                            Details : Gennova's synthetic, self-replicating India's first homegrown mRNA vaccine is in Phase III Clinical Trials for the treatment of COVID-19 is currently under final clinical trial stages. .

                            Brand Name : HGCO19

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            February 11, 2022

                            Lead Product(s) : mRNA-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HGCO19

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : HDT Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India

                            Details : Gennova Biopharmaceuticals, successfully completed a Phase 1 trial of its COVID-19 RNA vaccine candidate HGCO19 and Indian regulatory authorities have approved the start of pivotal Phase 2/3 trials.

                            Brand Name : HGCO19

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            August 31, 2021

                            Lead Product(s) : HGCO19

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : HDT Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed

                            Gennova Biopharmaceuticals

                            India arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HDT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Recipient : HDT Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HDT Bio Receives Notice to Proceed from FDA for U.S. Phase 1 Clinical Trial of RNA COVID-19 Vaccine

                            Details : HDT Bio has also developed HGCO19, a LION-based COVID-19 vaccine, in collaboration with Gennova Biopharmaceuticals of Pune, which is currently is being tested in India in a Phase 1/2 clinical trial.

                            Brand Name : HGCO19

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            July 01, 2021

                            Lead Product(s) : HDT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Recipient : HDT Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth